Growth hormone releasing hormone (GHRH), also referenced as growth hormone releasing factor (GHRF), somatocrinin, or somatoliberin, is an endogenous hypothalamic peptide widely used in laboratory research as a reference ligand for interrogating growth hormone releasing hormone receptor (GHRHR) signaling. In controlled experimental systems, GHRH supports mechanistic studies of receptor activation, second-messenger coupling, and downstream transcriptional responses in pituitary-derived cellular models and in-vivo animal frameworks. Because GHRH signaling is frequently modeled as a temporally patterned neuroendocrine input, research designs often focus on stimulus timing, receptor responsiveness, and pathway readouts under defined exposure conditions. These investigations emphasize receptor pharmacology and signaling kinetics rather than any applied or outcome-based interpretation.

Source: PubChem

Sequence: DL-Tyr-DL-Ala-DL-Asp-DL-Ala-DL-xiIle-DL-Phe-DL-xiThr-DL-Asn-DL-Ser-DL-Tyr-DL-Arg-DL-Lys-DL-Val-DL-Leu-Gly-DL-Gln-DL-Leu-DL-Ser-DL-Ala-DL-Arg-DL-Lys-DL-Leu-DL-Leu-DL-Gln-DL-Asp-DL-xiIle-DL-Met-DL-Ser-DL-Arg-DL-Gln-DL-Gln-Gly-DL-Glu-DL-Ser-DL-Asn-DL-Gln-DL-Glu-DL-Arg-Gly-DL-Ala-DL-Arg-DL-Ala-DL-Arg-DL-Leu
Molecular Formula: C₂₁₅H₃₅₈N₇₂O₆₆S
Molecular Weight: 5039.727 g/mol
PubChem CID: 44134750
CAS Number: 9034-39-3
Synonyms: Growth Hormone Releasing Factor, Somatocrinin, Somatoliberin

GHRH peptide variants have been reported across a range of sequence lengths in the literature (commonly described in the ~37–44 amino acid range). In preclinical workflows, variant length can be evaluated for receptor engagement behavior, potency relationships in cell-based assays, and stability in assay matrices, supporting sequence–activity mapping at GHRHR.

1. Receptor Pharmacology & Ligand Benchmarking

GHRH is used as a reference ligand in GHRHR activation assays to benchmark receptor responsiveness, concentration–response behavior, and signaling bias across second-messenger and phosphorylation readouts. These assays are commonly conducted in pituitary-derived cell models or engineered receptor-expression systems using cAMP-linked and downstream pathway endpoints.

2. Temporal Signaling & Desensitization Modeling

In systems biology and endocrine-axis modeling workflows, GHRH can be applied to probe how stimulus timing influences receptor resensitization, internalization kinetics, and downstream transcriptional programs. These designs evaluate mechanistic features of patterned signaling rather than any outcome-based interpretation.

3. Tissue Expression Datasets & Peripheral Signaling Hypotheses

Expression atlases and research datasets have reported GHRH transcripts across tissue contexts, motivating experimental designs that examine local GHRH/GHRHR signaling in controlled cellular systems and ectopic-expression models used in experimental biology.^[1]

Source: The Human Protein Atlas

4. Neuroendocrine Circuitry in Animal Models

Rodent studies have evaluated mechanistic relationships between GHRH signaling and sleep-state regulation, using genetic and pharmacologic perturbations to interrogate hypothalamic circuitry and receptor-linked phenotypes in vivo.^{[2], [3]}

GHRH engages GHRHR, a receptor class commonly investigated for G protein–coupled signaling that is frequently mapped to cAMP/PKA-associated second-messenger pathways in pituitary-relevant experimental systems. Downstream mechanistic readouts in cellular assays may include cAMP accumulation, kinase activation states, transcription factor modulation, and transcriptomic shifts in hormone-axis gene panels under controlled conditions.

In vivo, mechanistic studies often evaluate how hypothalamic peptide signaling interfaces with stress-related inputs and metabolic state, including models where upstream neuropeptide expression and pituitary responsiveness are perturbed. For example, obesity-associated changes in hypothalamic GHRH gene expression have been evaluated in genetically obese rodent models as a mechanistic framework for altered somatotropic signaling.^[4]

Preclinical investigations of GHRH include receptor-function studies in pituitary-derived and engineered cellular models, as well as in-vivo rodent studies probing neuroendocrine signaling interfaces. Published animal work has evaluated sleep-state regulation in mice with altered GHRH receptor function and has explored inflammatory pain signaling interfaces in rodent models of localized inflammatory hyperalgesia.^{[3], [5]}

Additional preclinical literature has examined pharmacologic antagonism of growth hormone–releasing hormone pathways in controlled cellular systems, including inflammation-linked proliferation readouts in epithelial model contexts.^[6]

Product characterization in RUO workflows commonly includes identity confirmation and purity profiling using analytical techniques such as HPLC and mass spectrometry. When documentation is provided for a specific lot, it is used for laboratory quality review (e.g., identity, purity, and consistency) within the experimental context.

1. “Tissue expression of GHRH – Summary – The Human Protein Atlas.”
2. F. Obal and J. M. Krueger, “GHRH and sleep,” Sleep Med. Rev., vol. 8, no. 5, pp. 367–377, Oct. 2004.
3. F. Obal, J. Alt, P. Taishi, J. Gardi, and J. M. Krueger, “Sleep in mice with nonfunctional growth hormone-releasing hormone receptors,” Am. J. Physiol. Regul. Integr. Comp. Physiol., vol. 284, no. 1, pp. R131-139, Jan. 2003.
4. I. Ahmad, J. A. Finkelstein, T. R. Downs, and L. A. Frohman, “Obesity-associated decrease in growth hormone-releasing hormone gene expression: a mechanism for reduced growth hormone mRNA levels in genetically obese Zucker rats,” Neuroendocrinology, vol. 58, no. 3, pp. 332–337, Sep. 1993.
5. R. S. Talhouk, N. E. Saadé, G. Mouneimne, C. A. Masaad, and B. Safieh-Garabedian, “Growth hormone releasing hormone reverses endotoxin-induced localized inflammatory hyperalgesia without reducing the upregulated cytokines, nerve growth factor and gelatinase activity,” Prog. Neuropsychopharmacol. Biol. Psychiatry, vol. 28, no. 4, pp. 625–631, Jul. 2004.
6. P. Popovics, A. V. Schally, L. Salgueiro, K. Kovacs, and F. G. Rick, “Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells,” Proc. Natl. Acad. Sci., vol. 114, no. 6, pp. 1359–1364, Feb. 2017.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.